http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-2007003341-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f3c9f34e6b4ac1569611ff5b7d06c362 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-00 |
| filingDate | 2005-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ffbed1acc075bce5ab8cad629d2edcf8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef00358d3e4e4851e6d17e2481896303 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_712867c3a16d4bcf662a867849b686e2 |
| publicationDate | 2007-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | MX-2007003341-A |
| titleOfInvention | INORGANIC SELENIUM FOR CANCER TREATMENT. |
| abstract | The present invention describes the use of selenate or its pharmaceutically acceptable salts, especially in supranutricional amounts, methods and compositions for inhibiting the growth or proliferation of tumor cells. The present invention also describes the use of selenate or its pharmaceutically acceptable salts in combination with one or both a hormone ablation therapy as a cytostatic agent or cytotoxic agent, to inhibit the growth or proliferation of tumor cells. In certain embodiments, the methods of the invention are useful for treating or preventing cancers, especially cancers in which the Akt signaling path is activated, such as prostate cancer. In addition, the present invention describes the use of selenate or its pharmaceutically acceptable salts in combination with a hormone ablation therapy and optionally a cytostatic agent or cytotoxic agent in methods and compositions for treating hormone-dependent cancers. |
| priorityDate | 2004-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 364.